Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with acute myeloid leukemia (AML) based on specific 2016 medical guidelines — but not the subtypes known as acute promyelocytic leukemia (APL) or biphenotypic AML.
- People whose AML is at a very low, hard-to-detect level (called MRD-positive) but who are otherwise considered to be in remission (cancer not visibly active), as measured by specialised laboratory tests.
- People who have completed at least one round of standard initial (induction) chemotherapy before joining the study.
- Adults aged 18 or older, at any stage of their treatment — including after initial treatment, during or after consolidation therapy, or before or after a stem cell transplant.
- People whose cancer cells carry a protein on their surface called CD33.
- People who are well enough to carry out basic daily activities (confirmed with trial site using a standard medical scale).
- People whose kidney function, liver function, and certain blood test results fall within acceptable ranges as determined by the trial team.
- People able to provide written consent to participate.
- Women who could become pregnant must have a negative pregnancy test before starting treatment in this trial.
- People re-joining this trial must have previously achieved a fully MRD-negative remission during their earlier participation.
Who may not be able to join:
- People who have received chemotherapy or radiation therapy within the 14 days before joining the study.
- People who are currently taking part in another clinical trial involving an experimental treatment.
- People with serious uncontrolled health conditions, such as an active uncontrolled infection, significant heart problems, or mental health or personal circumstances that would make it difficult to follow the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mary-Elizabeth Percival, Fred Hutch/University of Washington Cancer Consortium
Phone: 206-606-1320
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.